EFFECT OF AURANOFIN DOSE REGIMEN CHANGE UPON CELL-ASSOCIATED GOLD IN RHEUMATOID ARTHRITIC PATIENTS

  • 1 January 1981
    • journal article
    • research article
    • Vol. 8  (5) , 829-832
Abstract
The effect of changes in auranofin dose regimen in rheumatoid arthritis (RA) patients upon cell-associated and/or serum Au levels was examined. In 7 RA patients a reduction in daily dosage of auranofin from 3 mg bid [twice daily] to 3 mg qd [4 times per day] was correlated with a marked reduction (81-95%) in cell-associated Au; a return to the 3 mg bid dose level resulted in a reinstatement of cell-associated Au. These changes in cell-associated Au were not reflected in alteration of serum Au levels. This apparent lack of change in serum Au level as opposed to cell-associated Au suggests that this phenomenon warrants further investigation.